Sugi Predict

Sugi Predict / Compounds / SCHEMBL279461

SCHEMBL279461

SCHEMBL279461

COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)ncnn2c1CN1CCC(C(C)=O)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 8/20 0.59
▸ FLT3 P36888 2/20 0.59
▸ MAPK9 P45984 2/20 0.59
▸ RPS6KA3 P51812 2/20 0.59
▸ RET P07949 1/20 0.59
▸ BCR P11274 1/20 0.59
▸ FRK P42685 1/20 0.59
▸ PRKCD Q05655 1/20 0.59
▸ DDR1 Q08345 1/20 0.59
▸ MAP4K2 Q12851 1/20 0.59
▸ TNK1 Q13470 1/20 0.59
▸ RPS6KA1 Q15418 1/20 0.59
▸ MAP3K11 Q16584 1/20 0.59
▸ DDR2 Q16832 1/20 0.59
▸ RPS6KA6 Q9UK32 1/20 0.59
▸ BTK Q06187 6/20 0.43
▸ FGFR3 P22607 5/20 0.41
▸ KDR P35968 5/20 0.39
▸ PLK4 O00444 1/20 0.39
▸ AURKA O14965 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL276540 0.93 FGFR1 (0.58) FGFR1FLT3MAPK9RPS6KA3RET
SCHEMBL276864 0.91 FGFR1 (0.60) FGFR1FLT3MAPK9RPS6KA3RET
SCHEMBL276751 0.90 FGFR1 (0.70) FGFR1FLT3MAPK9RPS6KA3RET
SCHEMBL276407 0.90 FGFR1 (0.58) FGFR1FLT3MAPK9RPS6KA3RET
SCHEMBL274858 0.89 FGFR1 (0.57) FGFR1FLT3MAPK9RPS6KA3RET
SCHEMBL277034 0.88 FGFR1 (0.57) FGFR1FLT3MAPK9RPS6KA3RET
SCHEMBL328028 0.88 FGFR1 (0.57) FGFR1FLT3MAPK9RPS6KA3RET
SCHEMBL275487 0.87 FGFR1 (0.55) FGFR1FLT3MAPK9RPS6KA3RET
SCHEMBL275664 0.86 FGFR1 (0.52) FGFR1FLT3MAPK9RPS6KA3RET
SCHEMBL9979877 0.86 FGFR1 (0.52) FGFR1FLT3MAPK9RPS6KA3RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133995-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-13 — — US disclosed
US-8133995-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-13 — — US disclosed
US-20090281079-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis BAYER HEALTHCARE LLV (US) 2009-11-12 — — US disclosed
US-20090281079-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis BAYER HEALTHCARE LLV (US) 2009-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281079-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis CDK4, FLT4, CDKL4 FGFR1 19/4885FLT3 318/4885MAPK9 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.